Amyloid PET in AD, FTLD & PPA: Diagnosis, Functional & Structural Correlations

AD、FTLD 中的淀粉样蛋白 PET

• 批准号: 8113958
• 负责人: Gil Dan Rabinovici
• 金额: $ 15.94万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-30 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8113958
• 关键词: Alzheimer' s Disease; Amyloid; Amyloid beta-Protein; Amyloid deposition; Anatomy; Aphasia; Autopsy; Behavioral; Bilateral; Binding; Biological Markers; Biology; Biometry; Brain; Brain imaging; Brain region; Caring; Characteristics; Clinical; Clinical Distribution; Cognitive; Data Analyses; Dementia; Development; Diagnosis; Diagnostic; Diagnostic tests; Differential Diagnosis; Diffuse; Discrimination; Disease; Evaluation; Frontotemporal Lobar Degenerations; Genetic; Glucose; Goals; Gold; Grant; Healthcare; Histopathology; Image; Imaging Techniques; Instruction; K-Series Research Career Programs; Language; Lateral; Left; Lesion; Ligands; Magnetic Resonance Imaging; Measurement; Measures; Medial; Memory Disorders; Mentors; Molecular; Morbidity - disease rate; Neurobiology; Neurodegenerative Disorders; Neurons; Neurosciences; Parietal; Pathogenesis; Pathologic; Pathology; Patients; Pattern; Phenotype; Pittsburgh Compound-B; Positron-Emission Tomography; Primary Progressive Aphasia; Principal Investigator; Research; Research Personnel; Resources; Role; Scanning; Semantic Dementias; Series; Side; Structure; Syndrome; Temporal Lobe; Testing; Thick; Tracer; Training; Training Programs; Variant; Writing; age related; amyloid pathology; aphasic; base; cerebral atrophy; clinical Diagnosis; cognitive system; diagnosis standard; diagnostic accuracy; glucose metabolism; improved; in vivo; indexing; molecular imaging; mortality; neuroimaging; neuropathology; novel; research clinical testing; research study; responsible research conduct; tool; uptake

DESCRIPTION (provided by applicant): This is an application for a K-23 Mentored Career Development Award entitled "Amyloid PET in AD, FTLD & PPA: Diagnosis, Functional & Structural Correlations." The primary goal of the proposed research is to apply PET imaging with the amyloid-beta (AP) ligand Pittsburgh Compound-B (PIB) towards the differential diagnosis of dementia, while simultaneously studying the relationships between amyloid deposition, clinical presentation, and brain structure and function. Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) are two leading causes of dementia with distinct histopathologies. Primary progressive aphasia (PPA) is a clinical syndrome that can be caused by FTLD or (less commonly) AD pathology. PIB is a novel PET tracer that specifically binds Ap amyloid, a pathologic hallmark of AD that is not part of the FTLD spectrum. The specific aims of this study are: (1) To measure the utility of PIB-PET in distinguishing AD and FTLD; (2) To identify clinical features that predict the presence of Ap amyloid in PPA and FTLD, and thereby refine diagnostic criteria; (3) To study the relationships between clinical presentation, regional Ap amyloid deposition and neuronal functional and structural integrity using PIB-PET, FDG-PET, and MRI-based cortical thickness measurements. Overall, the proposal seeks to establish PIB-PET as an important clinical tool for improving diagnostic accuracy in dementia, and an important scientific tool for studying the role of Ap amyloid in the pathogenesis of AD. The applicant's long-term goal is to become an independent translational investigator in dementia with expertise in structural, functional and molecular neuroimaging. The applicant seeks training in: (1) neuroimaging, (2) neuropathology and neurobiology of -disease, (S)-biomarker analysis,. (4.) .biostatistics and. data analysis, (5) cognitive and systems neuroscience, (6) clinical dementia care, (7) presentation, Dublication and grant writing and (8) responsible conduct of research. The training program includes mplementing the proposed research plan, didactic courses and instruction from mentors and consultants. Dementia is a leading cause of age-related morbidity and mortality, and a growing strain on health-care resources. The proposed research studies the potential of a new brain imaging technique to improve diagnostic accuracy in dementia, and to study the biology of Alzheimer's disease.

描述（由申请人提供）：这是K-23指导职业发展奖的申请，标题为“ AD，FTLD和PPA中的淀粉样蛋白宠物：诊断，功能和结构相关性”。拟议的研究的主要目的是将PET成像与淀粉样蛋白β（AP）配体匹兹堡化合物B（PIB）应用于痴呆症的鉴别诊断，同时研究淀粉样蛋白沉积，临床表现，脑结构以及脑结构和功能之间的关系。阿尔茨海默氏病（AD）和额颞叶变性（FTLD）是具有不同组织病理学的两个主要原因。主要的进行性失语（PPA）是一种临床综合征，可能是由FTLD或（较少）AD病理引起的。 PIB是一种新型的宠物示踪剂，它专门结合AP淀粉样蛋白，AP淀粉样蛋白是AD的病理标志，它不是FTLD光谱的一部分。这项研究的具体目的是：（1）测量PIB-PET在区分AD和FTLD中的效用； （2）确定预测PPA和FTLD中AP淀粉样蛋白存在的临床特征，从而完善诊断标准； （3）使用PIB-PET，FDG-PET和基于MRI的皮质厚度测量值研究临床表现，区域AP淀粉样蛋白沉积与神经元功能和结构完整性之间的关系。总体而言，该提案试图建立PIB-PET作为提高痴呆症诊断准确性的重要临床工具，也是研究AP淀粉样蛋白在AD发病机理中的作用的重要科学工具。申请人的长期目标是成为具有结构，功能和分子神经影像学专业知识的独立翻译研究者。申请人寻求培训：（1）神经影像学，（2）-Disease的神经病理学和神经生物学，（S）-BIOMARKER Analysis，。 （4.）。数据分析，（5）认知和系统神经科学，（6）临床痴呆症护理，（7）介绍，出生和赠款写作以及（8）负责任的研究行为。培训计划包括介绍拟议的研究计划，教师和顾问的教学课程和指导。痴呆症是与年龄有关的发病率和死亡率的主要原因，并且对医疗保健资源的压力越来越大。拟议的研究研究了一种新的大脑成像技术的潜力，以提高痴呆症的诊断准确性，并研究阿尔茨海默氏病的生物学。